| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-05-15 14:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-05-13 14:00:00 |
Czytaj oryginał (ang.) |
| Best Biotech Stocks to Buy in 2025 |
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. |
marketbeat.com |
2025-05-13 12:10:10 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) |
globenewswire.com |
2025-05-12 11:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-05-11 14:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 |
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response |
globenewswire.com |
2025-05-10 14:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 |
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands. |
globenewswire.com |
2025-05-09 11:41:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine |
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 |
globenewswire.com |
2025-05-09 11:11:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 |
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands. |
globenewswire.com |
2025-05-09 10:15:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-05-08 14:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. |
globenewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out |
NEW YORK CITY, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-05-04 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-05-01 14:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 |
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two oral presentations and an upcoming poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, 2025, in Amsterdam, the Netherlands. |
globenewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-04-29 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect |
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-04-24 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm |
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: |
globenewswire.com |
2025-04-23 19:44:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-04-22 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-04-20 14:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-04-17 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-14 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect |
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-13 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out |
NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-12 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-11 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-10 12:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-09 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect |
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-07 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-06 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-05 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out |
NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-04 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out |
NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-03 12:00:00 |
Czytaj oryginał (ang.) |
| This Stock Just Doubled in 1 Day -- Is It Still a Buy? |
We are still pretty early in the new year, but some companies are already delivering outsize returns to their shareholders. Akero Therapeutics (AKRO -2.31%)is part of this group. |
fool.com |
2025-02-02 20:21:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-02-02 12:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-01-31 12:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares |
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering price of $48.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,093,750 shares of common stock, and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 1,958,247 shares of common stock at a public offering price of $47.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Akero. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $402.5 million. |
globenewswire.com |
2025-01-30 18:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accessnewswire.com |
2025-01-30 13:00:00 |
Czytaj oryginał (ang.) |
| AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study |
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX. |
zacks.com |
2025-01-29 13:16:10 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants |
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 5,333,420 shares of its common stock at a public offering price of $48.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 1,958,247 shares of common stock at a public offering price of $47.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are being offered by Akero. In addition, Akero has granted the underwriters a 30-day option to purchase up to an additional 1,093,750 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $350.0 million, excluding any exercise of the underwriters' option to purchase additional shares and excluding the exercise of any pre-funded warrants. The offering is expected to close on or about January 30, 2025, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2025-01-28 23:30:00 |
Czytaj oryginał (ang.) |
| Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients |
Company's stock surged over 100% after positive 96-week results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis due to MASH patients. The company achieved a significant reversal of cirrhosis, with 39% of patients showing improvement compared to 15% on placebo, highlighting EFX's efficacy. Upcoming catalysts include phase 3 SYNCHRONY studies targeting F1-F3 and F2-F3 MASH patients, with data expected in the first half of 2026 and 2027, respectively. |
seekingalpha.com |
2025-01-28 16:38:13 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Announces Proposed Public Offering of Common Stock |
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero. In addition, Akero intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2025-01-27 18:01:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out |
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2025-01-03 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2024-12-31 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2024-12-30 16:45:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2024-12-29 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2024-12-24 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out |
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2024-12-22 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out |
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2024-12-18 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2024-12-15 12:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO. |
accesswire.com |
2024-12-11 16:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 |
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan ® (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELF TM score (serum fibrosis biomarker) – |
globenewswire.com |
2024-11-15 13:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics to Present at the Jefferies London Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT. |
globenewswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update |
— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — |
globenewswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 |
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15-19, 2024, in San Diego. The presentations will highlight findings from the 96-week Phase 2b HARMONY study evaluating the efficacy and safety of lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3), along with insights from an analysis using AI and digital-based pathology. |
globenewswire.com |
2024-10-21 11:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm |
NEW YORK , Sept. 30, 2024 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) Shareholders should email Fletcher@fmoorelaw.com; please contact only if shares acquired before September 13, 2022 The investigation concerns misrepresentations to investors as to the true nature of the patient population that was being tested in Akero's SYMMETRY study. |
prnewswire.com |
2024-10-01 01:37:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference |
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference on Monday, October 7, 2024, at 11:00 a.m. E.T. |
globenewswire.com |
2024-09-30 11:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics: Good Candidate For The MASH Basket |
Akero Therapeutics' Efruxifermin (EFX) showed strong results in pre-cirrhotic MASH, but failed in cirrhotic MASH, impacting stock performance. The MASH market is highly competitive with many pipeline drugs and one approved drug, resmetirom, creating significant risk for AKRO. Akero has a solid cash runway until 2027, providing financial stability for ongoing trials and potential future data releases. |
seekingalpha.com |
2024-09-20 19:37:10 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH |
Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported the first patient was dosed in the Phase 3 SYNCHRONY Outcomes trial. |
globenewswire.com |
2024-09-09 11:00:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:45 a.m. E.T. in New York, NY. |
globenewswire.com |
2024-08-28 20:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO) |
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2024-08-23 15:46:00 |
Czytaj oryginał (ang.) |
| Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update |
-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH |
globenewswire.com |
2024-08-09 11:00:00 |
Czytaj oryginał (ang.) |